Country: United States
Language: English
Source: NLM (National Library of Medicine)
BALSALAZIDE DISODIUM (UNII: 1XL6BJI034) (BALSALAZIDE - UNII:P80AL8J7ZP)
Clinical Solutions Wholesale
BALSALAZIDE DISODIUM
BALSALAZIDE DISODIUM 750 mg
PRESCRIPTION DRUG
Abbreviated New Drug Application
BALSALAZIDE DISODIUM- BALSALAZIDE DISODIUM CAPSULE CLINICAL SOLUTIONS WHOLESALE ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BALSALAZIDE DISODIUM CAPSULES USP, 750 MG SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BALSALAZIDE DISODIUM CAPSULES USP. BALSALAZIDE DISODIUM CAPSULES USP FOR ORAL USE INITIAL U.S. APPROVAL: 2000 RECENT MAJOR CHANGES Drug Interactions (7) 2/2007 Postmarketing Experience (6.2) 3/2008 INDICATIONS AND USAGE Balsalazide Disodium Capsules USP are a locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in adults. (1) Safety and effectiveness of Balsalazide Disodium Capsules USP beyond 12 weeks in adults have not been established. (1) DOSAGE AND ADMINISTRATION Adult dose is three 750 mg balsalazide capsules 3 times a day (6.75 g/day) with or without food for 8 weeks. Some adult patients required treatment for up to 12 weeks. (2.1) Capsules may be swallowed whole or may be opened and sprinkled on applesauce, then chewed or swallowed immediately. (2.3, 12.3) DOSAGE FORMS AND STRENGTHS Capsules: 750 mg (3) (3) CONTRAINDICATIONS Patients with hypersensitivity to salicylates or to any of the components of Balsalazide Disodium Capsules USP or balsalazide metabolites. Hypersensitivity reactions may include, but are not limited to the following: anaphylaxis, bronchospasm, and skin reaction. (4) (4) WARNINGS AND PRECAUTIONS Exacerbation of the symptoms of ulcerative colitis was reported in adult patients. Observe patients closely for worsening of these symptoms while on treatment. (5.1) Prolonged gastric retention of balsalazide may occur in patients with pyloric stenosis. (5.2) ADVERSE REACTIONS Most common adverse reactions in adults (incidence ≥3% are headache, abdominal pain, diarrhea, nausea, vomiting, respiratory infection, and arthralgia. Adverse reactions in children were similar. (6.1) (6) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ROXANE LABORATORIES, Read the complete document